POLYCYTHEMIA VERA (PV)

This is a first-in-human study to test the safety and find the right dose of an experimental oral drug called PRT12396 for people with certain rare blood cancers. It will enroll about 100 adults with high-risk polycythemia vera or myelofibrosis. The main goal is to see how well t…

This program provides access to the drug ruxolitinib for patients with serious conditions like certain blood cancers and severe graft-versus-host disease. It is for people who have no other treatment options and cannot join a standard clinical trial. The program allows doctors to…

This study is testing whether adding a low-dose, inexpensive drug called methotrexate helps people with certain rare blood cancers. Researchers want to see if it safely reduces symptoms like enlarged spleen, fatigue, and abnormal blood cell counts when added to a patient's curren…

This study is testing an experimental drug called DISC-3405 for people with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells. The trial will enroll 60 adults who currently need frequent blood removal procedures to manage their conditi…

This study is testing an experimental pill called flonoltinib for adults with polycythemia vera (PV), a rare blood cancer, whose disease doesn't respond well to or who can't tolerate standard medications. The main goal is to see if different doses of the drug can safely control b…

This is a long-term observational study designed to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. for 5-10 years, collecting health records and patient surveys to track symptoms, treatm…